期刊
THROMBOSIS RESEARCH
卷 123, 期 -, 页码 S18-S21出版社
PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/S0049-3848(09)70137-9
关键词
Venous thromboembolism; Cancer; Risk factors; Biomarkers
资金
- National Cancer Institute [K23 CA120587]
- NATIONAL CANCER INSTITUTE [K23CA120587] Funding Source: NIH RePORTER
Cancer and its treatments are well-recognized risk factors for venous thromboembolism (VTE). Although solid tumors have historically been associated with VTE, more recent data suggest similar risk in patients with hematologic malignancies as well. The risk of VTE is not equal for at[ cancer patients or even in the same patient over time. In addition to well-known risk factors such as tumor site, stage, chemotherapy and comorbidities, candidate biomarkers have recently been identified including platelet and leukocyte counts, tissue factor and P-selectin. A validated risk model incorporating some of these risk factors and biomarkers has been shown to be predictive of VTE in cancer. VTE is associated with mortality, morbidity, potential delay in treatments for cancer and consumption of scarce health-care resources. Hence, reducing VTE with targeted prophylaxis could improve outcomes for cancer patients. (C) 2009 Elsevier Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据